Global Spine Biologics Market – Industry Trends - Forecast to 2026

  • Orthopedic Devices
  • Upcoming Report
  • May 2019
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Spine Biologics Market By Product (Bone Allografts, Bone Graft Substitute, Platelet Rich Plasma, Bone Marrow Aspirate Therapy), Surgery type (Anterior Cervical Discectomy and Fusion (ACDF); Transforamenal Lumbar Interbody Fusion (TLIF); Anterior Lumbar Interbody Fusion (ALIF); Lateral Lumbar Interbody Fusion (LLIF) among others), End-User (Hospitals, Spinal Surgery Centers, Orthopedic Clinics, Others), By Geography (North America, Europe, Asia-Pacific, South America, Middle East % Africa) – Industry Trends & Forecast to 2026

Market Analysis: Global Spine Biologics Market

Global Spine Biologics Market is expected to rise from its initial estimated value of USD 1.69 billion in 2018 to an estimated value of USD 2.5 billion by 2026 registering a CAGR of 4.9% in the forecast period of 2019-2026.

Market Definition: Global Spine Biologics Market

Biologics assist the natural process of bone formation. They can also be used as products that can cure the disease or degenerated discs. Biologics for spine includes all the biological materials that play a role in a spinal procedure; these are one of the most innovative advances in spine surgical treatment. These are implants used in lieu allografts or as a support for bones in and around the spinal region. They are used through spine fusion surgery for the therapy of spinal deformities such as trauma, tumors, degenerative disc disease & spinal cord injuries. They betterment  bone formation and activate spinal fusion.

Market Drivers

  • Rising incidence of spinal distortion is becoming more predominant in the aging population.
  • Rising healthcare expenditure in developing nations owing to growing income levels
  • Rising obesity cases, are leading to the increased demand for biologics in their treatments.
  • Awareness on the newly developed spine treatment techniques and devices amongst individuals fosters to the growth of this market.
  • Innovative technological advancements, with newly developed spine treatment techniques and devices.
  • Rising demand of minimally invasive spine surgeries.
  • The quick healing, minimum postoperative time and the capability to activate cellular expansion, serve as an advantage for the biologics market.

Market Restraints

  • Scarcity of expertise and professional knowledge is acting as a restraint for the market
  • Lack of patient understanding and awareness is one of the restraint for the market
  • Cost of surgery and the unfavorable reimbursement scenario.

Segmentation: Global Spine Biologics Market

By Product

  • Bone Allografts

    • Machined bone allograft
    • Demineralized bone matrix

  • Bone Graft Substitute

    • Synthetic Bone Grafts
    • Demineralized Bone Matrix (DBM)
    • Bone Morphogenetic Proteins (BMP)

  • Platelet Rich Plasma
  • Bone Marrow Aspirate Therapy

By Surgery Type:

  • Anterior Cervical Discectomy and Fusion (ACDF)
  • Transforamenal Lumbar Interbody Fusion (TLIF)
  • Anterior Lumbar Interbody Fusion (ALIF)
  • Lateral Lumbar Interbody Fusion (LLIF)
  • Others

By End User

  • Hospitals
  • Spinal Surgery Centers
  • Orthopedic Clinics
  • Others

By Geography

  • North America

    • US
    • Canada
    • Mexico

  • South America

    • Brazil
    • Argentina
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Malaysia
    • Indonesia
    • Thailand
    • Philippines
    • Rest of Asia-Pacific

  • Middle East and Africa

    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East and Africa

Key Developments in the Market:

  • In February 2017, ChoiceSpine acquires Exactech’s spine assets, which was a part of the restructuring and divesture charges of Exactech. The terms and the conditions of the transaction were not released. With this acquisition ChoiceSpine would have the access to Exactech’s distribution channels in Spain, Germany & Portugal. They already had their distribution channels in Italy and Mexico, this acquisition would widen their international footprint.
  • In March 2018, CellRight Technologies Signed a Multi-Year Distribution Agreement With Arthrex Inc, a manufacturer of orthopedic surgical solutions. Cellright, is a company which manufactures osteobiologics which are used in orthopedic, spine, foot and ankles, intensifying the healing chances of problems caused by trauma & disease. The multi-year commitment would provide surgeons entrance to certified osteobiologics and advanced surgical instrumentation and techniques helping to achieve better patient outcomes.

Competitive Analysis: Global Spine Biologics Market

The global spine biologics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of spine biologics market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Spine Biologics Market

Few of the major market competitors currently working in the spine biologics market report include Arthrex, Inc., Cesca Therapeutics Inc., DePuy Synthes, Orthopaedic Seminar, Exactech, Inc., K2M, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc., NuVasive Inc., Orthofix Holdings, Inc., Regen Lab USA LLC, RTI Surgical Holdings, Inc., Stryker, Wright Medical Group N.V., XTANT MEDICAL, Zimmer Biomet, Smith & Nephew, Dr PRP USA LLC, and others.

Research Methodology: Global Spine Biologics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global spine biologics market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

SKU-

1. INTRODUCTION

       1.1. OVERVIEW OF THE SPINE BIOLOGICS MARKET
       1.2. MARKET SEGMENTATION & COVERAGE
                1.2.1. CURRENCY AND PRICING 
                1.2.2. LIMITATION
                1.2.3. STAKEHOLDERS

2. RESEARCH METHODOLOGY

       2.1. KEY TAKEAWAYS
       2.2. ARRIVING AT THE GLOBAL SPINE BIOLOGICS MARKET SIZE
                2.2.1. MARKET CRACKDOWN APPROACH 
                2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
                2.2.3. DATA TRIANGULATION
                2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
                2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
                2.2.6. PORTER’S FIVE FORCES MATRIX
       2.3. GLOBAL SPINE BIOLOGICS MARKET: RESEARCH SNAPSHOT
       2.4. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. PREMIUM INSIGHTS

       4.1. OVERVIEW
       4.2. GLOBAL SPINE BIOLOGICS MARKET: KEY PRIMARY INSIGHTS
       4.3. MARKET OVERVIEW
                4.3.1. DRIVERS
                 4.3.2. RESTRAINTS
                4.3.3. OPPURTUNITIES
                4.3.4. THREATS
       4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5. SPINE BIOLOGICS MARKET, BY PRODUCT TYPE

       5.1. OVERVIEW
       5.2. BONE GROWTH SUBSTITUTES
                5.2.1. DEMINERALIZED BONE MATRIX (DBM)
                5.2.2. BONE MORPHOGENETIC PROTEINS (BMP)
                5.2.3. SYNTHETIC BONE GRAFTS
       5.3. BONE ALLOGRAFTS
       5.4. PLATELET RICH PLASMA (PRP)
       5.5. BONE MARROW ASPIRATE CONCENTRATE (BMAC)

6. SPINE BIOLOGICS MARKET, BY SURGERY TYPE

       6.1. OVERVIEW
       6.2. ANTERIOR CERVICAL DISECTOMY AND FUSION (ACDF)
       6.3. TRANSFORAMENAL LUMBAR INTERBODY FUSION (TLIF)
       6.4. ANTERIOR LUMBAR INTERBODY FUSION (ALIF)
       6.5. LATERAL LUMBAR INTERBODY FUSION (LLIF)
       6.6. OTHERS

7. SPINE BIOLOGICS MARKET, BY END USER

       7.1. OVERVIEW
       7.2. HOSPITALS
       7.3. SPINAL SURGERY CENTERS
       7.4. ORTHOPEDIC CLINICS
       7.5. OTHERS

8. SPINE BIOLOGICS MARKET, BY GEOGRAPHY

       8.1. COUNTRYWISE SPINE BIOLOGICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
                8.1.1. NORTH AMERICA
                              8.1.1.1. U.S.
                              8.1.1.2. CANADA
                              8.1.1.3. MEXICO
                8.1.2. EUROPE
                              8.1.2.1. GERMANY
                              8.1.2.2. FRANCE
                              8.1.2.3. U.K.
                              8.1.2.4. ITALY
                              8.1.2.5. SPAIN
                              8.1.2.6. RUSSIA
                              8.1.2.7. TURKEY
                              8.1.2.8. BELGIUM
                              8.1.2.9. NETHERLANDS
                              8.1.2.10. SWITZERLAND
                              8.1.2.11. REST OF EUROPE
                8.1.3. ASIA-PACIFIC (APAC)
                              8.1.3.1. JAPAN
                              8.1.3.2. CHINA
                              8.1.3.3. SOUTH KOREA
                              8.1.3.4. INDIA
                              8.1.3.5. AUSTRALIA
                              8.1.3.6. SINGAPORE
                              8.1.3.7. THAILAND
                              8.1.3.8. MALAYSIA
                              8.1.3.9. INDONESIA
                              8.1.3.10. PHILIPPINES
                              8.1.3.11. REST OF APAC
                8.1.4. LATIN AMERICA
                              8.1.4.1. BRAZIL
                              8.1.4.2. REST OF LATIN AMERICA
                8.1.5. MIDDLE EAST AND AFRICA
                              8.1.5.1. SOUTH AFRICA
                              8.1.5.2. REST OF MIDDLE EAST AND AFRICA
       8.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

9. SPINE BIOLOGICS MARKET: COMPETITIVE LANDSCAPE

       9.1. GLOBAL SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
       9.2. U.S. SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
       9.3. EUROPE SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
       9.4. APAC SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
       9.5. SOUTH AMERICA SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
       9.6. MIDDLE EAST AND AFRICA  SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
       9.7. MERGERS & ACQUISITIONS
       9.8. NEW PRODUCT DEVELOPMENT & APPROVALS
       9.9. EXPANSIONS
       9.10. REGULATORY CHANGES
       9.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

10. SPINE BIOLOGICS MARKET, COMPANY PROFILES

       10.1. APPLIED BIOLOGICS
                         10.1.1. OVERVIEW
                         10.1.2. SWOT ANALYSIS
                         10.1.3. PRODUCT PORTFOLIO
                         10.1.4. REVENUE ANALYSIS
                         10.1.5. ANALYSTS VIEW
       10.2. ARTHREX, INC.
                         10.2.1. OVERVIEW
                         10.2.2. SWOT ANALYSIS
                         10.2.3. PRODUCT PORTFOLIO
                         10.2.4. REVENUE ANALYSIS
                         10.2.5. ANALYSTS VIEW
       10.3. CESCA THERAPEUTICS
                         10.3.1. OVERVIEW
                         10.3.2. SWOT ANALYSIS
                         10.3.3. PRODUCT PORTFOLIO
                         10.3.4. REVENUE ANALYSIS
                         10.3.5. ANALYST VIEW
       10.4. DEPUY SYNTHES
                         10.4.1. OVERVIEW
                         10.4.2. SWOT ANALYSIS
                         10.4.3. PRODUCT PORTFOLIO
                         10.4.4. REVENUE ANALYSIS
                         10.4.5. ANALYSTS VIEW
       10.5. DMP SPINE
                         10.5.1. OVERVIEW
                         10.5.2. SWOT ANALYSIS
                         10.5.3. PRODUCT PORTFOLIO
                         10.5.4. REVENUE ANALYSIS
                         10.5.5. ANALYSTS VIEW
       10.6. DR. PRP AMERICA LLC.
                         10.6.1. OVERVIEW
                         10.6.2. SWOT ANALYSIS
                         10.6.3. PRODUCT PORTFOLIO
                         10.6.4. REVENUE ANALYSIS
                         10.6.5. ANALYSTS VIEW
       10.7. EXACTECH, INC.
                         10.7.1. OVERVIEW
                         10.7.2. SWOT ANALYSIS
                         10.7.3. PRODUCT PORTFOLIO
                         10.7.4. REVENUE ANALYSIS
                         10.7.5. ANALYSTS VIEW
       10.8. K2M, INC.
                         10.8.1. OVERVIEW
                         10.8.2. SWOT ANALYSIS
                         10.8.3. PRODUCT PORTFOLIO
                         10.8.4. REVENUE ANALYSIS
                         10.1.5. ANALYSTS VIEW
       10.9. LATTICE BIOLOGICS
                         10.9.1. OVERVIEW
                         10.9.2. SWOT ANALYSIS
                         10.9.3. PRODUCT PORTFOLIO
                         10.9.4. REVENUE ANALYSIS
                         10.9.5. ANALYSTS VIEW
       10.10. MEDTRONIC
                         10.10.1. OVERVIEW
                         10.10.2. SWOT ANALYSIS
                         10.10.3. PRODUCT PORTFOLIO
                         10.10.4. REVENUE ANALYSIS
                         10.10.5. ANALYSTS VIEW
       10.11. NUVASIVE, INC.
                         10.11.1. OVERVIEW
                         10.11.2. SWOT ANALYSIS
                         10.11.3. PRODUCT PORTFOLIO
                         10.11.4. REVENUE ANALYSIS
                         10.11.5. ANALYSTS VIEW
       10.12. ORTHOFIX HOLDINGS, INC.
                         10.12.1. OVERVIEW
                         10.12.2. SWOT ANALYSIS
                         10.12.3. PRODUCT PORTFOLIO
                         10.12.4. REVENUE ANALYSIS
                         10.12.5. ANALYSTS VIEW
       10.13. REGENLAB S.A.
                         10.13.1. OVERVIEW
                         10.13.2. SWOT ANALYSIS
                         10.13.3. PRODUCT PORTFOLIO
                         10.13.4. REVENUE ANALYSIS
                         10.13.5. ANALYSTS VIEW
       10.14. RTI SURGICAL
                         10.14.1. OVERVIEW
                         10.14.2. SWOT ANALYSIS
                         10.14.3. PRODUCT PORTFOLIO
                         10.14.4. REVENUE ANALYSIS
                         10.14.5. ANALYSTS VIEW
       10.15. STRYKER CORPORATION
                         10.15.1. OVERVIEW
                         10.15.2. SWOT ANALYSIS
                         10.15.3. PRODUCT PORTFOLIO
                         10.15.4. REVENUE ANALYSIS
                         10.15.5. ANALYSTS VIEW
       10.16. WRIGHT MEDICAL
                         10.16.1. OVERVIEW
                         10.16.2. SWOT ANALYSIS
                         10.16.3. PRODUCT PORTFOLIO
                         10.16.4. REVENUE ANALYSIS
                         10.16.5. ANALYSTS VIEW
       10.17. X-SPINE SYSTEMS
                         10.17.1. OVERVIEW
                         10.17.2. SWOT ANALYSIS
                         10.17.3. PRODUCT PORTFOLIO
                         10.17.4. REVENUE ANALYSIS
                         10.17.5. ANALYSTS VIEW
       10.18. ZIMMER BIOMET
                         10.18.1. OVERVIEW
                         10.18.2. SWOT ANALYSIS
                         10.18.3. PRODUCT PORTFOLIO
                         10.18.4. REVENUE ANALYSIS
                         10.18.5. ANALYSTS VIEW

11. APPENDIX

12. ABOUT DATA BRIDGE MARKET RESEARCH

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART